Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 5.31%
As of Monday, October 19, Damora Therapeutics, Inc.’s DMRA share price has surged by 5.31%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 8.31%
As of Tuesday, October 06, Damora Therapeutics, Inc.’s DMRA share price has dipped by 8.31%, which has investors questioning if this is right time to buy.Michael Rose
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 8.95%
As of Tuesday, October 06, Damora Therapeutics, Inc.’s DMRA share price has dipped by 8.95%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 5.46%
As of Tuesday, October 06, Damora Therapeutics, Inc.’s DMRA share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 6.78%
As of Wednesday, September 23, Damora Therapeutics, Inc.’s DMRA share price has dipped by 6.78%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,138.4 | $208.8 | 48% |
|
| Shares Out (Mil) | 61.1 | 53.9 | 52% |
|
| Institutional Ownership | 98.7% | 93.1% | 81% |
|
| Float (Mil) | 40.9 | 41.4 | 42% |
|
| Beta | 1.48 | 0.95 | 82% |
|
| Avg Daily Volume (000s) | 495 | 614 | 58% |
|
| Price Change (52-week) |
57.9% | 45.3% | 88% |
|
| Growth | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (43.2%) | (10.2%) | 9% |
|
| EPS (5yr) | 4.2% | 15.7% | 37 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.5%) | (15.7%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.435) | ($1.895) | ($2.173) | |
| Month Ago EPS | ($0.435) | ($1.893) | ($2.143) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.395) | ($1.755) | ($2.078) | |
| Year/Year Chg | 10.4% | (98.8%) | (98.3%) | |
| Financials | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($263) | ($44) | 5% |
|
| EPS (TTM) | ($9.876) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($45) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,503 | $174 | 46% |
|
| Valuation | DMRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.95 | 2.09 | 67% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (94.3%) | (47.2%) | 6% |
|
| ROE | (132.8%) | (54.2%) | 7% |
|
| Liabilities to Assets | 5.1% | 29.1% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Damora Therapeutics, Inc. did not pass any screens on 10/16/2026.
